Ophthotech announces results from third phase III trial of Fovist in Wet AMD

Tuesday, August 15, 2017

Ophthotech announced that the pre-specified primary endpoint of mean change in visual acuity at 12 months was not achieved in its phase III clinical trial investigating the superiority of Fovista (pegpleranib) anti-PDGF therapy in combination with Eylea (aflibercept) or Avastin (bevacizumab) anti-VEGF therapy compared to Eylea or Avastin monotherapy for the treatment of wet age-related macular degeneration (AMD). The addition of 1.5mg of Fovista to an Eylea or Avastin regimen did not result in benefit as measured by the mean change in visual acuity at the 12-month time point.

[Read More]

Novartis, Ophthotech ink agreement for Fovista

Wednesday, May 21, 2014

Ophthotech, a biopharmaceutical company specializing in the development of novel therapeutics to treat diseases of the eye, has entered into an ex-U.S. licensing and commercialization agreement with Novartis Pharmaceuticals focused on the treatment of wet age-related macular degeneration (AMD). Ophthotech grants Novartis exclusive rights to commercialize Ophthotech’s lead product candidate, Fovista, in markets outside the U.S. while Ophthotech retains sole rights to commercialize Fovista in the U.S.

[Read More]

Ophthotech raises $175M for phase III Fovista anti-PDGF combo therapy in wet AMD

Wednesday, May 29, 2013

Ophthotech, a privately held biopharmaceutical company, has raised $175 million to finance a global phase III clinical program of its lead compound Fovista, an anti-platelet-derived growth factor (PDGF), in combination with anti-VEGF therapy for the treatment of neovascular age-related macular degeneration (wet AMD). The multi-national phase III trial is expected to begin in the third quarter of 2013 and enroll nearly 1,900 patients in more than 200 centers worldwide.

[Read More]